Home >> Market >> Mutual Fund >> Scheme Snapshot
 
Get Quote
 
 
Gainers Losers Latest NAV Scheme Profile  
 
Search Scheme 

SCHEME SNAPSHOT

ICICI Prudential Banking and Financial Services
Fund : ICICI Prudential Mutual Fund
Category : Equity - Sector Fund
Type : Open Ended
NAV(17/01/2017) 44.6300
Percentage Returns :
1 Month Ago : 4.84%
3 Months Ago : -1.8%
1 Year Ago : 41.68%
Snapshot
Inception Date 7/9/2008 Fund Manager Mr. Vinay Sharma
Initial Price 10.00 Min. Invest. Rs.5000
Objectives ICICI Prudential Banking and Financial Services Fund is an Open-ended equity scheme that seeks to generate long-term capital appreciation to unitholders from a portfolio that is invested predominantly in equity and equity related securities of companies engaged in banking and financial services.
Entry Load nil
Exit Load If the amount sought to be redeemed or switched out is invested for a period of upto one year from the date of allotment; 1% of the applicable NAV. Else - Nil.
Trailing Returns
  1 Mth 3 Mths 1 Yr 3 Yrs
Scheme4.84-1.841.6828.73
Category3.43-1.9816.7560.41
Sensex2.82-1.0711.378.94
Nifty3.18-1.4412.9110.28
NAV Chart
Other Options  Asset Allocation
OptionsNAV
Dividend32.4900 (17/01/2017)
Growth44.6300 (17/01/2017)
Holding DateValue (Rs. Cr)
30/11/20161226.84
31/10/20161194.64
30/09/20161134.04
31/08/20161123.53
31/07/20161078.60
Mutual Fund Registrar
One BKC, A-Wing, 13th Floor, Bandra Kurla Complex, Mumbai, Maharashtra, India - 400051
Email : enquiry@icicipruamc.com
Web : http://www.icicipruamc.com
Computer Age Management Services (P) Ltd.
 

Sector Watch

 
  Company
Name
NSE
Current
NSE
Change (%)
NSE
Volume
BSE
Current
BSE
Change (%)
BSE
Volume
926.10 2.25 319,644
925.10 2.06 40,432
188.95 0.59 2,435,356
188.55 0.35 202,731
86.90 1.11 7,922,410
86.95 1.34 1,213,221
2,699.70 -1.07 161,391
2,704.30 -0.94 13,247
941.15 0.68 430,941
940.95 0.63 33,501
21,100.90 -1.47 12,980
21,096.80 -1.51 5,878

TOP MF News

KOTAK SENSEX ETF has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Qu...

Company News

Drug firm Zydus Cadila today said it has received approval from the US health regulator to market methotrexate tablets a chemother...